Cargando…

Strategies to overcome drug resistance using SHP2 inhibitors

Encoded by PTPN11, the SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is widely recognized as a carcinogenic phosphatase. As a promising anti-cancer drug target, SHP2 regulates many signaling pathways such as RAS-RAF-ERK, PI3K-AKT and JAK-STAT. Meanwhile, SHP2 plays a signifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Meng, Gao, Shan, Elhassan, Reham M., Hou, Xuben, Fang, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727779/ https://www.ncbi.nlm.nih.gov/pubmed/35024315 http://dx.doi.org/10.1016/j.apsb.2021.03.037

Ejemplares similares

Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors
por: Heynen, Guus J. J. E., et al.
Publicado: (2022)

Targeting histone deacetylases for cancer therapy: Trends and challenges
por: Liang, Tao, et al.
Publicado: (2023)

Therapeutic Suppression of FAK-AKT Signaling Overcomes Resistance to SHP2 Inhibition in Colorectal Carcinoma
por: Li, Ye, et al.
Publicado: (2021)

Impact of SHP2 tyrosine phosphorylation on the development of acquired resistance to allosteric SHP2 inhibitors
por: Franciosa, Giulia, et al.
Publicado: (2023)

Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP
por: Hao, Fang, et al.
Publicado: (2021)

Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance
por: Nguyen, Ngoc Minh, et al.
Publicado: (2022)

Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD–Driven AML
por: Pfeiffer, Anamarija, et al.
Publicado: (2022)

Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
por: Szumilak, Marta, et al.
Publicado: (2021)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

SHP2 is a multifunctional therapeutic target in drug resistant metastatic breast cancer
por: Chen, Hao, et al.
Publicado: (2020)

Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
por: Sha, Fern, et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Emerging strategies to overcome resistance to third-generation EGFR inhibitors
por: Shi, Kunyu, et al.
Publicado: (2022)

Revisiting Proteasome Inhibitors: Molecular Underpinnings of Their Development, Mechanisms of Resistance and Strategies to Overcome Anti-Cancer Drug Resistance
por: Leonardo-Sousa, Carlota, et al.
Publicado: (2022)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

Off‐target inhibition by active site‐targeting SHP2 inhibitors
por: Tsutsumi, Ryouhei, et al.
Publicado: (2018)

Cleavable PEGylation: a strategy for overcoming the “PEG dilemma” in efficient drug delivery
por: Fang, Yan, et al.
Publicado: (2017)

Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras
por: Song, Xiaoling, et al.
Publicado: (2021)

SC-2001 Overcomes STAT3-mediated Sorafenib Resistance through RFX-1/SHP-1 Activation in Hepatocellular Carcinoma()()
por: Su, Jung-Chen, et al.
Publicado: (2014)

Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect
por: Sun, Ziying, et al.
Publicado: (2022)

Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors
por: Hou, Aohan, et al.
Publicado: (2020)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

Development of Antibiofilm Therapeutics Strategies to Overcome Antimicrobial Drug Resistance
por: Nadar, Sahaya, et al.
Publicado: (2022)

Strategies to overcome HIV drug resistance-current and future perspectives
por: Temereanca, Aura, et al.
Publicado: (2023)

PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer
por: Hou, Xuben, et al.
Publicado: (2021)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression
por: Wang, Yao-Chen, et al.
Publicado: (2018)

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
por: Tojjari, Alireza, et al.
Publicado: (2023)

HDAC inhibitors with potential to overcome drug resistance in castration-resistant prostate cancer
por: Biersack, Bernhard, et al.
Publicado: (2022)

Targeting RFWD2 as an Effective Strategy to Inhibit Cellular Proliferation and Overcome Drug Resistance to Proteasome Inhibitor in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2021)

Corrigendum to: Off‐target inhibition by active site‐targeting SHP2 inhibitors
por: Tsutsumi, Ryouhei, et al.
Publicado: (2019)

Novel Therapies and Strategies to Overcome Resistance to Anti-HER2-Targeted Drugs
por: Gámez-Chiachio, Manuel, et al.
Publicado: (2022)

Comparison of Strategies to Overcome Drug Resistance: Learning from Various Kingdoms
por: Ogawara, Hiroshi
Publicado: (2018)

Modulation of redox homeostasis: A strategy to overcome cancer drug resistance
por: Li, Yang, et al.
Publicado: (2023)

Overcoming Mycobacterium tuberculosis Drug Resistance: Novel Medications and Repositioning Strategies
por: Sachan, Rohan Samir Kumar, et al.
Publicado: (2023)

Combination strategies to overcome drug resistance in FLT(+) acute myeloid leukaemia
por: Yang, Jingmei, et al.
Publicado: (2023)

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
por: Song, Zhendong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5oqkmhqikl3m3fs6660vq8gsue